[EN] SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY [FR] DÉRIVÉS DE 1,3,4-THIADIAZOLE SPIRO-CONDENSÉS POUR INHIBER L'ACTIVITÉ DE LA KINÉSINE KSP
摘要:
本发明涉及以下式(I)的化合物(其中X、R1、R2、R3、p、E、环A和环B的定义如本文所述)。本发明还涉及包括这些化合物的组合物(包括药学上可接受的组合物),单独或与一个或多个额外治疗剂的组合物,并且涉及它们在抑制KSP动力蛋白活性以及治疗与KSP动力蛋白活性相关的细胞增殖性疾病或紊乱的用途的方法。Formula I [化学式应按照纸质形式中的摘要插入在此处。]
Synthesis, determination of absolute configuration, and biological evaluation of spiro-fused thiadiazoline inhibitors of kinesin spindle protein (KSP)
作者:Angie R. Angeles、Liping Yang、Chaoyang Dai、Andrew Brunskill、Andrea D. Basso、M. Arshad Siddiqui
DOI:10.1016/j.tetlet.2010.09.066
日期:2010.12
A facile and highly convergent synthesis of biologically active spiro-fused thiadiazoline KSP inhibitors is reported. The highlights of the synthesis include the Michael reaction and cyclization of thiosemicarbazone to 1,3,4-thiadiazoline. This chemistry lends itself to the preparation of (+)-2, a potent and orally bioavailable anti-cancer agent, and to the development of a structure-activity relationship program. (C) 2010 Elsevier Ltd. All rights reserved.
SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY
申请人:Merck Sharp & Dohme Corp.
公开号:EP2220061B1
公开(公告)日:2016-02-17
COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY
申请人:Siddiqui M. Arshad
公开号:US20110123435A1
公开(公告)日:2011-05-26
The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. Formula I
SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS
申请人:Siddiqui M. Arshad
公开号:US20120070370A1
公开(公告)日:2012-03-22
The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.